Edition:
United States

Active Biotech AB (ACTI.ST)

ACTI.ST on Stockholm Stock Exchange

11.40SEK
11:29am EST
Change (% chg)

-0.20kr (-1.72%)
Prev Close
11.60kr
Open
11.20kr
Day's High
11.65kr
Day's Low
11.00kr
Volume
49,455
Avg. Vol
85,936
52-wk High
15.24kr
52-wk Low
7.37kr

ACTI.ST

Chart for ACTI.ST

About

Active Biotech AB is a Sweden-based company that focuses on pharmaceutical research and development in medical fields in which the immune system plays a central role. The Company’s research portfolio primarily includes projects for the development of drugs for the treatment of autoimmune and inflammatory diseases and cancer. As... (more)
No analyst recommendations are available for ACTI.ST.

Overall

Beta: 2.26
Market Cap(Mil.): kr1,123.16
Shares Outstanding(Mil.): 96.82
Dividend: --
Yield (%): --

Financials

  ACTI.ST Industry Sector
P/E (TTM): -- 45.90 30.76
EPS (TTM): -0.94 -- --
ROI: -20.62 -1.00 14.82
ROE: -42.75 -0.71 16.24

BRIEF-Active Biotech says receives European patent for tasquinimod

* Says the European Patent Office grants patent for tasquinimod for treatment of multiple myeloma

Jan 09 2017

BRIEF-Active Biotech to raise SEK 55 mln via rights issue

* Active biotech carries out rights issue of approximately 55 million Swedish crowns ($6.03 million)

Nov 14 2016

BRIEF-Active Biotech Q3 loss narrows

* Cash and cash equivalents at the end of the period SEK 39.9 million Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

Nov 14 2016

BRIEF-Active Biotech partners with NeoTX for commercialization of ANYARA

* Reg-Active Biotech and NeoTX enter into a partnership for the development and commercialization of ANYARA for immuno-oncology

Oct 26 2016

BRIEF-Active Biotech postpones publication of interim report

* Reg-Active Biotech postpone publication of the interim report

Oct 26 2016

BRIEF-Active Biotech updates on laquinimod development

* Active Biotech update on laquinimod development: U.S, Food and Drug Administration rescinds special protocol assessment for laquinimod Source text for Eikon: Further company coverage:

Sep 19 2016

Earnings vs. Estimates